David Lubogo
ID: UNCST-2020-R014473
|
Metabolic Syndrome among Females of Reproductive age in Wakiso district, Central Uganda: Risk factors and Effectiveness of a Community based Nutrition Education Intervention
REFNo: HS1281ES
General objective: To investigate the prevalence of, and factors associated with metabolic syndrome (MetS) and evaluate the effect of a community based nutrition education intervention among females of reproductive age with MetS in Wakiso district, Central Uganda in order to contribute information for the design of interventions for MetS.
Specific objectives
1. To determine the prevalence of, and factors associated with Metabolic Syndrome.
2. To determine optimal WC cut off points for MetS.
3. To determine the effectiveness of a 12 -week community-based nutrition education and counseling intervention for metabolic syndrome on selected cardiovascular outcomes (BP), biochemical outcomes (HDL, TGS, blood sugar), anthropometric measures (WC, weight), behavioral outcomes (dietary intake, physical activity), and on knowledge as an outcome.
4. To explore the female and health care provider perceptions/perspectives towards the nutrition promotion intervention on MetS among female of reproductive age in South Central Uganda.
|
Wakiso,
Wakiso,
|
Uganda |
2021-12-28 |
2024-12-28 |
840 |
Females aged 15- 49 years in Wakiso district. |
Strengthening Education and Training Capacity in Sexual and Reproductive Health and Rights in Uganda (SET-SRHR) and the Government of Uganda |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
JIM ARINAITWE
ID: UNCST-2021-R012572
|
Quit4Life: Adapting and Evaluating a Phone-Based Tobacco Uses Cessation Program for People Living with HIV in Uganda and Zambia.
REFNo: HS1762ES
The goal of the study is to adapt and evaluate the efficacy of a phone-based tobacco cessation intervention for PLWH in Uganda and Zambia in five years. The primary objective of the study is to promote smoking cessation among HIV infected persons. Specifically, 1) adapt a standard short message service (SMS) for tobacco cessation program, 2) Nicotine Replacement Therapy, 3) compare the efficacy of our SMS-based program tailored to meet the needs of PLWH (Quit4Life+) to the current standard of care.
|
Arua, Adumi HCIV, Omugo HCIV and River Oli HCIV
Moroto, Loputuk HCIII, Nadunget HCIII and Tapac HCIII
|
Uganda |
2021-12-28 |
2024-12-28 |
Total Sample size is 800 with 400 from Uganda and 400 from Zambia |
The study will include males and females of consenting age attending HIV services at Health III, IV, District/Regional Referral Hospitals |
National Institute of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
JULIET MWANGA-AMUMPAIRE
ID: UNCST-2022-R009420
|
An open-label, multicentre, randomized, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19
REFNo: HS1789ES
Primary objective: to compare the efficacy of alternative treatment strategies versus control on the risk of progression to severe respiratory disease
The secondary objectives are:
 To compare the safety of each study arm to control, up to Day 21 of follow-up
 To compare the rate of hospitalizations due to COVID-19 in each study arm versus control
 To compare the time to hospitalization due to COVID-19 in each study arm versus control
 To compare the rate of hospitalizations for other reason than Covid-19 in each study arm versus control
 To compare the disease-free rate in each study arm versus control
 To compare the death rate in each study arm versus control
 To compare time to worsening of SpO2 < 93in each study arm versus control
 To compare the capacity to prevent severe progression between study arms
 To identify risk factors for severe progression
 To assess efficacy in sub-groups of patients e.g. with pre-existing conditions/co-morbidities, by age group, sex, BMI, timeframe between onset of symptoms and randomization.
|
Mbarara, Mbarara Medical Cell
|
Uganda |
2021-12-07 |
2024-12-07 |
175 |
1. Male or female patients,
2. Adult’s  18 years of age at the time of screening. Children > 12 years of age may be included if recommended by the DSMB after the first analysis.
3. COVID-19 confirmed by molecular biology or validated antigenic test |
Drugs for Neglected Diseases Initiative (DNDi) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Flavia Matovu Kiweewa
ID: UNCST-2021-R013337
|
PURPOSE 1: GS-US-412-5624/ A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection. Version 2.0, dated 10 March 2021.
REFNo: HS1920ES
1. Primary Objectives
i) To evaluate the efficacy of LEN for HIV PrEP in AGYW at risk of HIV infection.
ii) To evaluate the efficacy of F/TAF for HIV PrEP in AGYW at risk of HIV infection.
2. Secondary Objectives/ end points
i) To compare the efficacy of LEN with F/TDF for HIV PrEP in AGYW at risk of HIV infection.
ii) To evaluate the efficacy of LEN for HIV PrEP in AGYW at risk of HIV infection in participants adherent to LEN.
iii) To evaluate the efficacy of F/TAF for HIV PrEP in AGYW at risk of HIV infection in participants adherent to F/TAF.
iv) To compare the efficacy of F/TAF with F/TDF for HIV PrEP in AGYW at risk of HIV infection.
v) To evaluate the safety and tolerability of LEN, F/TAF, and F/TDF for HIV PrEP in AGYW at risk of HIV infection.
vi) To evaluate the safety and tolerability of LEN and F/TAF for HIV PrEP in AGYW ≥ 16 to < 18 years of age who have sex with male partners and are at risk for HIV infection.
3. Exploratory objectives
i) To assess the adherence rate to LEN as assessed by on-time LEN injection
ii) To assess LEN plasma levels
iii) To assess the adherence rate to F/TAF and F/TDF using intracellular TFV-DP levels in DBS.
iv) To evaluate the acceptability of a once every 26 weeks LEN injection for HIV PrEP in AGYW at risk of HIV infection.
v) To assess LEN plasma levels during pregnancy.
vi) To explore concentrations of hormonal contraceptives in LEN participants.
|
Mityana, Mityana
Hoima, Hoima county
Masaka, Masaka
Kalangala, Kalangala
|
Uganda |
2021-11-25 |
2024-11-25 |
The study will be conducted in 2 parts: a cross-sectional study (Incidence Phase) and a randomized blinded study (Randomized Phase). The Incidence Phase of the study will remain open until the backg |
Cisgender AGYW who have sex with male partners, at risk for HIV infection ≥ 16 to ≤ 25 years of age. |
Gilead Sciences Inc. |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Kamya Moses
ID: UNCST-2020-R014203
|
Enhancing immunity to malaria in young children with effective chemoprevention
REFNo: HS1763ES
To compare the incidence of malaria from 4 weeks to 4 years of age among children born to mothers randomized to receive intermittent preventative therapy in pregnancy (IPTp) with monthly sulfadoxine pyrimethamine (SP) alone, monthly DP alone, or both monthly SP+DP.
To compare the incidence of malaria from 2-4 years of age among children randomized to receive IPT in childhood (IPTc) with monthly DP from 8 weeks to 1 year of age vs. monthly DP from 8 weeks to 2 year of age vs. no IPTc.
To compare innate and adaptive effector and regulatory responses between children randomized to different IPT arms.
|
Busia, Masafu
|
Uganda |
2021-11-24 |
2024-11-24 |
924 HIV-uninfected infants |
Children both male and female, 4 weeks to 4 years of age, resident of Busia District |
Division of Microbiology and Infectious Diseases (DMID) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
